MNPR - Monopar Therapeutics GAAP EPS of -$0.19 beats by $0.03 May, 11 2023 10:03 AM Monopar Therapeutics Inc. 2023-05-11 10:03:26 ET Monopar Therapeutics press release ( NASDAQ: MNPR ): Q1 GAAP EPS of -$0.19 beats by $0.03 . Cash, cash equivalents and shortterm investments as of March 31, 2023, were $11.7 million. For further details see: Monopar Therapeutics GAAP EPS of -$0.19 beats by $0.03